OxRML/AgentSLR huggingface dataset:
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 9.09 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 6 / 66 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Sangakai, West Pokot
Setting: Population based, Unspecified
Sample size: 66
Study period: Feb 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 11.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 13 / 113 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Kanyerus, West Pokot
Setting: Population based, Unspecified
Sample size: 113
Study period: Feb 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 4.11 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 3 / 73 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Shaba, West Pokot
Setting: Population based, Unspecified
Sample size: 73
Study period: Feb 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 1.67 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 60 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Longarkau, West Pokot
Setting: Population based, Unspecified
Sample size: 60
Study period: Feb 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 3.85 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 2 / 52 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Pkotong, West Pokot
Setting: Population based, Unspecified
Sample size: 52
Study period: Feb 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 7.11 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 33 / 464 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Disaggregated by: Age, Region
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: West Pokot
Setting: Population based, Unspecified
Sample size: 464
Study period: Feb 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 1.59 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 63 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Elelea, Turkana
Setting: Population based, Unspecified
Sample size: 63
Study period: Aug 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 25 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Prigan, Turkana
Setting: Population based, Unspecified
Sample size: 25
Study period: Aug 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 61 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Kare Edome, Turkana
Setting: Population based, Unspecified
Sample size: 61
Study period: Aug 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 69 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Nayanaesanyati, Turkana
Setting: Population based, Unspecified
Sample size: 69
Study period: Aug 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 56 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Old Gunner, Turkana
Setting: Population based, Unspecified
Sample size: 56
Study period: Aug 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 139 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Lowarengak, Turkana
Setting: Population based, Unspecified
Sample size: 139
Study period: Aug 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0.24 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 413 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Disaggregated by: Age, Region
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Turkana
Setting: Population based, Unspecified
Sample size: 413
Study period: Aug 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 63.1 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 12 / 19 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Czech Republic
Location: University Hospital Bulovka, Prague
Setting: Travel based, Unspecified
Sample size: 19
Study period: Jan 2004 - Dec 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 42.1 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 8 / 19 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Czech Republic
Location: University Hospital Bulovka, Prague
Setting: Travel based, Unspecified
Sample size: 19
Study period: Jan 2004 - Dec 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 84.2 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 16 / 19 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Czech Republic
Location: University Hospital Bulovka, Prague
Setting: Travel based, Unspecified
Sample size: 19
Study period: Jan 2004 - Dec 2019
Parameter: Human delay - Onset to Admission to care (Human delay)
Value: 7 Days (Median)
Exponent (base 10): 0
Uncertainty: 3 - 19 (IQR)
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Czech Republic
Location: University Hospital Bulovka, Prague
Setting: Travel based, Unspecified
Sample size: 19
Study period: Jan 2004 - Dec 2019
Parameter: Human delay - Onset to Recovery/non-Infectiousness (Human delay)
Value: 5 Days (Median)
Exponent (base 10): 0
Uncertainty: 4 - 6 (IQR)
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Czech Republic
Location: University Hospital Bulovka, Prague
Setting: Travel based, Unspecified
Sample size: 19
Study period: Jan 2004 - Dec 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 31.4 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 30 - 32.9 (95% CI)
Numerator/denominator: 1268 / 4035 (method: )
Disaggregated by: Age, Occupation, Other, Sex
Population: General population, sex: Both, ages 1 to 50
Country: United States
Location: Ponce, Puerto Rico
Setting: Household based, Unspecified
Sample size: 4090
Study period: Apr 2018 - May 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:  Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 0.1 - 74.7
Case definition: Lab confirmed
Seroprevalence adjustment: Adjusted
Statistical approach: Estimated model parameter
Disaggregated by: Age, Method, Other, Sex
Population: General population, sex: Both, ages 5 to 65
Country: Brazil
Location: Recife
Setting: Household based, Urban area
Sample size: 2070
Study period: Aug 2018 - Feb 2019
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Suspected
Numerator/denominator: 38 / 400 (method: Naive)
Seroprevalence adjustment: Unspecified
Population: Persons under investigation, sex: Unspecified, ages 18 to 
Country: Malaysia
Location: Sabah
Setting: Hospital based, Unspecified
Sample size: 400
Study period: 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 6 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 4 - 8 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 24 / 38 (method: Naive)
Seroprevalence adjustment: Unspecified
Population: Persons under investigation, sex: Unspecified, ages 18 to 
Country: Malaysia
Location: Sabah
Setting: Hospital based, Unspecified
Sample size: 38
Study period: 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Case definition: Suspected
Numerator/denominator: 36 / 400 (method: Naive)
Seroprevalence adjustment: Unspecified
Population: Persons under investigation, sex: Unspecified, ages 18 to 
Country: Malaysia
Location: Sabah
Setting: Hospital based, Unspecified
Sample size: 400
Study period: 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Suspected
Numerator/denominator: 16 / 418 (method: Naive)
Seroprevalence adjustment: Unspecified
Population: Blood donors, sex: Unspecified, ages 18 to 
Country: Malaysia
Location: Sabah
Setting: Hospital based, Unspecified
Sample size: 418
Study period: 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 1.4 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 0.65 - 3 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 6 / 16 (method: Naive)
Seroprevalence adjustment: Unspecified
Population: Blood donors, sex: Unspecified, ages 18 to 
Country: Malaysia
Location: Sabah
Setting: Hospital based, Unspecified
Sample size: 26
Study period: 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Case definition: Suspected
Numerator/denominator: 15 / 418 (method: Naive)
Seroprevalence adjustment: Unspecified
Population: Blood donors, sex: Unspecified, ages 18 to 
Country: Malaysia
Location: Sabah
Setting: Hospital based, Unspecified
Sample size: 418
Study period: 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0.5 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 0.13 - 1.8 (95% CI)
Case definition: Probable
Numerator/denominator: 2 / 38 (method: Naive)
Seroprevalence adjustment: Unspecified
Population: Persons under investigation, sex: Unspecified, ages 18 to 
Country: Malaysia
Location: Sabah
Setting: Hospital based, Unspecified
Sample size: 38
Study period: 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 1.4 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 0.65 - 3 (95% CI)
Case definition: Probable
Numerator/denominator: 6 / 16 (method: Naive)
Seroprevalence adjustment: Unspecified
Population: Blood donors, sex: Unspecified, ages 18 to 
Country: Malaysia
Location: Sabah
Setting: Hospital based, Unspecified
Sample size: 26
Study period: 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 27.3 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 20.7 - 35.1 (95% CI)
Numerator/denominator: 41 / 150 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 18 to 65
Country: Ethiopia
Location: Itang special district, Lare district
Setting: Community based, Unspecified
Sample size: 150
Study period: Oct 2018 - Jun 2019
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 1.4 Percentage (%) ()
Exponent (base 10): 0
Case definition: Suspected
Numerator/denominator: 14 / 1006 (method: )
Disaggregated by: Symptoms
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages 18 to 45
Country: Nigeria
Location: Jos
Setting: Hospital based, Unspecified
Sample size: 1006
Study period: 1 Apr 2019 - 31 Jan 2022
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 0.4 Percentage (%) ()
Exponent (base 10): 0
Case definition: Suspected
Numerator/denominator: 4 / 1006 (method: )
Disaggregated by: Symptoms
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages 18 to 45
Country: Nigeria
Location: Jos
Setting: Hospital based, Unspecified
Sample size: 1006
Study period: 1 Apr 2019 - 31 Jan 2022
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 19.2 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 0.16 - 0.21 (95% CI)
Case definition: Unspecified
Numerator/denominator: 167 / 871 (method: Naive)
Disaggregated by: Age, Other, Region, Sex, Symptoms
Population: General population, sex: Both, ages 0 to 80
Country: Nigeria
Location: 3 states in Nigeria Nigeria, Abia State in Southern Nigeria, and Kaduna
State in Northern Nigeria
Setting: Hospital based, Unspecified
Sample size: 871
Study period: Dec 2020 - Nov 2021
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.12 No units (Mean)
Exponent (base 10): 0
Uncertainty: 0.8 - 1.5 (95% CrI)
Bounds: 0.7 - 1.6
Statistical approach: Estimated model parameter
Disaggregated by: Method, Time
Reproduction number method: Compartmental model Unspecified
Trimester exposed: Unspecified
Population: Persons under investigation, sex: , ages  to 
Country: Fiji
Setting: Population based, Unspecified
Study period: 2013 - 2018
Parameter: Attack rate (Attack rate)
Value:  Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 46 - 53
Statistical approach: Unspecified
Disaggregated by: Method
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Fiji
Setting: Population based, Unspecified
Study period: May 2013 - Nov 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 13.2 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 115 / 872 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Region, Sex
Population: General population, sex: Both, ages 5 to 
Country: Malaysia
Setting: Community based, Rural area
Sample size: 872
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 57 / 374 (method: )
Seroprevalence adjustment: Naive
Population: General population, sex: Male, ages 5 to 
Country: Malaysia
Setting: Community based, Rural area
Sample size: 374
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 58 / 498 (method: )
Seroprevalence adjustment: Naive
Population: General population, sex: Female, ages 5 to 
Country: Malaysia
Setting: Community based, Rural area
Sample size: 498
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 17.3 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 14 / 81 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Lubuk Legong
Setting: Community based, Rural area
Sample size: 81
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 22 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 20 / 91 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Sungai Perah
Setting: Community based, Rural area
Sample size: 91
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 6.9 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 6 / 87 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Tumboh Hangat
Setting: Community based, Rural area
Sample size: 87
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 4.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 3 / 67 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Jekjok
Setting: Community based, Rural area
Sample size: 67
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 4 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 4 / 101 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Sangwai
Setting: Community based, Rural area
Sample size: 101
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 22 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Paya Pelong
Setting: Community based, Rural area
Sample size: 22
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 9.4 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 12 / 90 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Paya Sendayan
Setting: Community based, Rural area
Sample size: 90
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 22.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 8 / 45 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Donglai Baru
Setting: Community based, Rural area
Sample size: 45
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 21.3 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 10 / 47 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Paya Lebar
Setting: Community based, Rural area
Sample size: 47
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 22.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 27 / 120 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Dusun Kubur
Setting: Community based, Rural area
Sample size: 120
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 17.4 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 8 / 46 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Ulu Kelaka
Setting: Community based, Rural area
Sample size: 46
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 5.9 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 17 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Bukit Payung
Setting: Community based, Rural area
Sample size: 17
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 5.3 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 19 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Pasir Intan
Setting: Community based, Rural area
Sample size: 19
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 7.7 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 3 / 39 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 5 to 
Country: Malaysia
Location: Semanggar
Setting: Community based, Rural area
Sample size: 39
Study period: Unspecified
Parameter: Mutations - evolutionary rate (Mutations)
Value: 0.6 Substitutions/site/year (Mean)
Exponent (base 10): -3
Uncertainty: 0.3 - 0.8 (95% CI)
Bounds: 0.1 - 5.3
Statistical approach: Estimated model parameter
Population: Unspecified, sex: , ages  to 
Country: Multi-country: Americas (n = 13), Asia (n = 5), Oceania (n = 2)
Setting: Unspecified, 
Sample size: 40
Study period: 1966 - 2017
Parameter: Mutations - evolutionary rate (Mutations)
Value: 0.8 Substitutions/site/year (Mean)
Exponent (base 10): -3
Uncertainty: 0.5 - 1.1 (95% CI)
Bounds: 0.3 - 6
Statistical approach: Estimated model parameter
Population: Unspecified, sex: , ages  to 
Country: Multi-country: Africa (n = 2), Americas (n = 11), Asia (n = 8), Oceania (n = 2), Europe (n = 1)
Setting: Unspecified, 
Sample size: 40
Study period: 2013 - 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 10.8  ()
Exponent (base 10): 0
Uncertainty: 6.9 - 15.7 (95% CI)
Numerator/denominator: 23 / 214 (method: Naive)
Disaggregated by: Age, Occupation, Other, Sex
Population: Other, sex: Both, ages 18 to 
Country: Zambia
Location: Lukanga swamps, Central Province of Zambia
Setting: Community based, Unspecified
Sample size: 214
Study period: Oct 2016 - Nov 2016